One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

Google's DeepMind launches AlphaGenome, an artificial intelligence model that predicts gene expression from DNA sequence.

Now Google’s DeepMind division says it’s made a leap in trying to understand the code with AlphaGenome, an AI model that ...

Demonstrators gathered outside Google DeepMind's London office on Monday to accuse the company of reneging on a key AI ...

An artificial intelligence (AI) model developed by Google DeepMind in London could help scientists to make sense of this ...

Google DeepMind is rolling out an on-device version of its Gemini Robotics AI model that allows it to operate without an ...

DeepMind has been exploring the potential risks of AI since before ChatGPT appeared, and Shane Legg, one of the company’s cofounders, has led an “AI safety” group within the company for years.

DeepMind has its own internal ethics board, the Institutional Review Committee (IRC), with representatives from all areas of the company, chaired by its chief operating officer, Lila Ibrahim.